Formycon AG (ETR:FYB)
23.70
-0.30 (-1.25%)
At close: Jan 23, 2026
Formycon AG Employees
Formycon AG had 250 employees as of December 31, 2024. The number of employees increased by 12 or 5.04% compared to the previous year.
Employees
250
Change (1Y)
12
Growth (1Y)
5.04%
Revenue / Employee
€192,296
Profits / Employee
€660,688
Market Cap
418.65M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 250 | 12 | 5.04% | 250 | 0 |
| Dec 31, 2023 | 238 | 33 | 16.10% | 238 | 0 |
| Dec 31, 2022 | 205 | 34 | 19.88% | 205 | 0 |
| Dec 31, 2021 | 171 | 40 | 30.53% | 125 | 46 |
| Dec 31, 2020 | 131 | 18 | 15.93% | 103 | 28 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Fresenius SE & Co. KGaA | 176,486 |
| Bayer Aktiengesellschaft | 91,864 |
| Siemens Healthineers AG | 73,840 |
| Merck KGaA | 59,020 |
| RHÖN-KLINIKUM Aktiengesellschaft | 14,067 |
| Gerresheimer AG | 12,142 |
| MEDICLIN Aktiengesellschaft | 10,472 |
| Stratec SE | 1,387 |
Formycon AG News
- 12 days ago - EQS-DD: Formycon AG: Active Ownership Fund SICAV SIF SCS, sell - Wallstreet:Online
- 12 days ago - EQS-DD: Formycon AG: Active Ownership Fund SICAV SIF SCS, Verkauf • news - Onvista
- 4 weeks ago - EQS-News: FDA approves another interchangeable Ranibizumab Biosimilar, Nufymco – Strengthening US Presence with Zydus as Commercialization Partner - Wallstreet:Online
- 6 weeks ago - Formycon AG: Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda (Pembrolizumab), in the U.S. and Canada - Finanz Nachrichten
- 6 weeks ago - Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda (Pembrolizumab), in the U.S. and Canada - Wallstreet:Online
- 6 weeks ago - EQS-News: Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda (Pembrolizumab), in the U.S. and Canada - Wallstreet:Online
- 7 weeks ago - Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda biosimilar candidate FYB206 for the MENA Region - Finanz Nachrichten
- 7 weeks ago - Formycon, MS Pharma Sign Commercialization Partnership For Keytruda Biosimilar - Nasdaq